Joel Beatty's questions to Amylyx Pharmaceuticals Inc (AMLX) leadership • Q3 2024
Question
Joel Beatty of Baird asked how the company thinks about balancing its remaining cash among its lead program avexitide, other pipeline assets with potentially lower success probabilities, and the potential for business development.
Answer
James Frates, Chief Financial Officer, emphasized that avexitide is the clear lead asset due to its strong data, safety, and late-stage development. He affirmed the company's cash runway extends into 2026, which is sufficient to get through the avexitide Phase III data readout. While prepared to tighten belts if needed, he stated current plans support all key programs and their upcoming milestones.